Medications that induce central sleep apnoea (e.g., opioids, baclofen and ticagrelor)

Ludger Grote

Source: 5th Sleep and Breathing Conference
Number: 71

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ludger Grote. Medications that induce central sleep apnoea (e.g., opioids, baclofen and ticagrelor). 5th Sleep and Breathing Conference

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Too much or too little (ventilation): pathophysiology of central sleep apnoea and hypoventilation (including opioids, treatment-emergent etc.)
Source: 5th Sleep and Breathing Conference
Year: 2019

Daytime sleepiness in patients on intrathecal chronic opioid (IT) therapy is not related to sleep disordered breathing (SDB)
Source: Annual Congress 2011 - Comorbid obstructive sleep apnoea (OSA) and OSA comorbidities
Year: 2011

Concomitant benzodiazepine and opioids decrease sleep apnoea risk in chronic pain patients
Source: ERJ Open Res, 6 (3) 00093-2020; 10.1183/23120541.00093-2020
Year: 2020

Treatment effects of sleep apnoea: where are we now?
Source: Eur Respir Rev 2007; 16: 146-168
Year: 2007

Does chronic opioid therapy alter the pattern of sleep apnea?
Source: Eur Respir J 2004; 24: Suppl. 48, 446s
Year: 2004

Adaptive servo-ventilation (ASV) therapy for sleep disordered breathing (SDB) associated with opioid medications
Source: Annual Congress 2007 - Sleep apnoea and adaptive servo–ventilation
Year: 2007

Serotonin in obstructive sleep apnea patients with before and after the continuous positive airway pressure treatment
Source: Annual Congress 2005 - Upper airway interventions in OSA patients
Year: 2005

Treatment options for central sleep apnea (including auto-CPAP)
Source: Annual Congress 2005 - Central sleep apnoea
Year: 2005

Pharmacological management of sleep-disordered breathing
Source: Eur Respir Mon 2010; 50: 321-339
Year: 2010

Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem
Source: Eur Respir J, 50 (6) 1701344; 10.1183/13993003.01344-2017
Year: 2017

Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report
Source: Eur Respir J 2015; 46: 1202-1205
Year: 2015

Sleep apnea associated with opioids is effectively treated withadaptive pressure support servo-ventilation
Source: Annual Congress 2010 - Complex sleep apnoea, opioids, adaptive servoventilation, bilateral positive airway pressure and continuous positive airway pressure
Year: 2010

The effects of opioids on perioperative outcomes in patients with obstructive sleep apnoea
Source: International Congress 2016 – Comorbid sleep apnoea in specific clinical entities and differential diagnosis of sleep disorders
Year: 2016

Efficacy and safety of modafinil as an adjunctive therapy for excessive sleepiness associated with obstructive sleep apnoea
Source: Eur Respir J 2004; 24: Suppl. 48, 116s
Year: 2004

Central sleep apnea
Source: Respipedia Article
Year: 2017

Tolerability of modafinil in disorders of sleep and wakefulness
Source: Eur Respir J 2004; 24: Suppl. 48, 115s
Year: 2004

The 5-min pupillary alertness test is sensitive to modafinil: a placebo controlled study in patients with obstructive sleep apnea (OSA)
Source: Annual Congress 2007 - Treatment options in obstructive sleep apnoea
Year: 2007

Night treatment with long acting ß2 agonists in mild COPD patients with sleep apnoea syndrome
Source: Eur Respir J 2007; 30: Suppl. 51, 74s
Year: 2007

Varenicline administration for smoking cessation may reduce apnea hypnea index in sleep apnea patients
Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing
Year: 2021